CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018)

CytomX Therapeutics (CTMX) posted Long-Term Deferred Tax of $87.6 million for Q4 2018.

CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018) Analysis & Trends

CytomX Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $87.6 million for Q4 2018.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $87.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $87.6 million (changed N/A YoY) and the FY2018 annual result came in at $87.6 million, changed N/A from the prior year.
Long-Term Deferred Tax was $87.6 million for Q4 2018 at CytomX Therapeutics.
Across five years, Long-Term Deferred Tax topped out at $87.6 million in Q4 2018 and bottomed at $87.6 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	CytomX Therapeutics	590.32 Mn	243.61 Mn	-

Download Data

Date	Value
Dec 31, 2018	87.60 Mn